From professional translators, enterprises, web pages and freely available translation repositories.
acting out
actuación (psicología)
Last Update: 2014-12-09
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis
c linical investigation of slow- a c t ing anti- rheumatic medic inal products in rheumatoid arthritis
each participant shall also participate in a target2 cug , as specified by the ssp-providing cbs acting as the swift service administrator for the ssp .
each participant shall also participate in a target2 cug , as specified by the ssp-providing cbs acting as the swift service administrator for the ssp .
perche', a cinque ore dallo spettacolo, ci vorrebbe il miglior acting coach che il mondo abbia mai visto per fargli avere successo.
porque, con el espectáculo a cinco horas desde ahora, le llevaría al mejor profesor de interpretación el mundo nunca visto hacer que su show sea un éxito.
quando nasce un desidero, voglio dire, un vero desiderio, quello che voi chiamate acting out, sarebbe saggio che ci ricordassimo come ha vissuto elizabeth taylor.
cuando llega el deseo, es decir, el deseo, al que llamáis actuar mal, sería interesante recordar como vivió elizabeth taylor.
(25) public investments are regarded state aid if the investments are decided under circumstances which would not be acceptable for a private investor acting under normal market economy principles.
(25) public investments are regarded state aid if the investments are decided under circumstances which would not be acceptable for a private investor acting under normal market economy principles.
(16) public loans must be regarded to benefit undertakings if they are decided upon in circumstances which would not be acceptable to a private investor acting under normal market-economy principles.
(16) public loans must be regarded to benefit undertakings if they are decided upon in circumstances which would not be acceptable to a private investor acting under normal market-economy principles.
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
